Advanced Development and Validation of Emerging Biospecimen Science Technologies for Basic and Clinical Cancer Research (R33 Clinical Trial Not Allowed) | RFA CA 25 004

Frequently Asked Questions (FAQs)

What is the funding opportunity?

This opportunity is NCI RFA-CA-25-004, titled "Advanced Development and Validation of Emerging Biospecimen Science Technologies for Basic and Clinical Cancer Research (R33 Clinical Trial Not Allowed)." It is a discretionary NIH grant in the health and education activity area (CFDA 93.394) and is part of NCI's Innovative Molecular Analysis Technologies (IMAT) Program.

What is the overall goal of this NOFO?

The goal is to move promising biospecimen-related technologies beyond early proof-of-concept into a more mature, rigorously validated state, so they can be used with greater confidence in cancer research and, where appropriate, in clinical care workflows.

What kinds of technologies are the focus of this program?

The focus is on technologies that improve how cancer-relevant biospecimens and their derivatives are collected, handled, processed, preserved, and stored. This includes practical tools, devices, assays, and companion methods intended to reduce errors and variability introduced before measurement occurs (the pre-analytical phase).

What does "biospecimen and their derivatives" mean in this context?

Based on the description provided, this refers to cancer-relevant biospecimens as well as materials derived from them for molecular or cellular analysis, with an emphasis on ensuring integrity throughout collection, handling, processing, preservation, and storage.

What is the "pre-analytical phase," and why is it important here?

The pre-analytical phase is the period before an actual measurement is made, when samples can degrade, be contaminated, or otherwise change in ways that distort downstream results. This NOFO emphasizes reducing or measuring these sources of error and variability.

What types of problems is NCI trying to solve with this funding?

NCI is aiming to address pre-analytical errors and variability, such as sample degradation, contamination, or changes that can distort downstream molecular or cellular results. The program is interested in technologies that preserve/protect sample integrity or provide clearer verification criteria and quality assessment/quality control methods to determine whether a specimen is fit for a given analysis.

Does this opportunity support early-stage feasibility or proof-of-concept work?

No. The NOFO is not an early feasibility program. Applicants are expected to have already addressed major feasibility gaps and to provide supportive preliminary data showing the core concept works.

What stage of work is NCI expecting applicants to propose?

NCI is looking for the next step after proof-of-concept: further development, optimization, and especially rigorous validation. The intent is to produce convincing validation evidence and a technology that is ready to accelerate and strengthen cancer research and translational applications.

What kinds of validation evidence are expected?

The NOFO emphasizes demonstrating performance characteristics relevant to real-world use, including reproducibility, robustness across operators or sites, sensitivity to common handling variations, and the ability to reduce or at least measure pre-analytical degradation of targeted analytes.

What does "rigorous validation" mean for this grant based on the description?

Based on the information provided, rigorous validation means generating evidence that the technology performs reliably under realistic conditions, including across different operators and/or sites, and that it addresses pre-analytical degradation or variability in a measurable way.

Are clinical trials allowed under this funding mechanism?

No. The NOFO explicitly states "Clinical Trial Not Allowed" for this R33 mechanism, indicating projects should remain in the development and validation lane rather than testing interventions in human participants as clinical outcomes trials.

If clinical trials are not allowed, what kind of work is appropriate?

Appropriate work includes technology development, optimization, and validation for biospecimen collection/handling/processing/preservation/storage, along with verification criteria and QA/QC approaches to assess specimen fitness for intended analyses.

What cancer research areas could benefit from the supported technologies?

The NOFO describes end-use relevance for cancer biology studies, early detection and screening research, clinical diagnosis, treatment-related research, and epidemiology.

How does this opportunity relate to cancer health disparities?

The NOFO highlights relevance to issues that contribute to cancer health disparities, such as enabling higher-quality sampling in low-resource or decentralized settings, or reducing bias introduced by uneven specimen handling across populations and sites.

What is the maximum award amount (award ceiling)?

The award ceiling listed in the provided information is $300,000.

How many awards does NCI expect to make?

The provided information indicates an expectation of approximately 2 awards.

What is the application due date?

The original application closing date provided is 2025-10-03.

When was this opportunity created?

The opportunity was created on 2024-12-16.

Who is the sponsoring agency?

The sponsoring agency is the National Cancer Institute (NCI), part of NIH.

What program within NCI is associated with this NOFO?

This opportunity sits within NCI's broader Innovative Molecular Analysis Technologies (IMAT) Program.

What organizations are eligible to apply?

Eligibility is broad and includes many types of U.S. and non-U.S. organizations. Listed eligible applicants include state, county, city or township, and special district governments; independent school districts; public and state-controlled institutions of higher education; private institutions of higher education; federally recognized Native American tribal governments; tribal organizations (including those other than federally recognized governments); public housing authorities and Indian housing authorities; nonprofits with and without 501(c)(3) status (other than institutions of higher education); for-profit organizations (other than small businesses); small businesses; and other entities.

Are non-U.S. (non-domestic) entities eligible?

Yes. The information provided explicitly includes non-domestic (non-U.S.) entities among eligible applicants.

Are small businesses eligible to apply?

Yes. Small businesses are listed among eligible applicant types.

Are for-profit organizations eligible to apply?

Yes. For-profit organizations (other than small businesses) are listed as eligible, and small businesses are also listed separately as eligible.

Are universities and colleges eligible?

Yes. Public and state-controlled institutions of higher education and private institutions of higher education are both listed as eligible.

Are specific institution types encouraged to apply (for example, MSIs)?

The NOFO highlights additional eligible applicant categories such as Historically Black Colleges and Universities (HBCUs), Hispanic-serving institutions, Tribally Controlled Colleges and Universities (TCCUs), Alaska Native and Native Hawaiian Serving Institutions, Asian American Native American Pacific Islander Serving Institutions (AANAPISIs), and others, reflecting an intent to encourage broad participation.

Are faith-based or community-based organizations eligible?

Yes. Faith-based or community-based organizations are explicitly highlighted among additional eligible applicant categories.

Are federal agencies eligible to apply?

Yes. Eligible federal agencies are highlighted among additional eligible applicant categories.

Are U.S. territories or possessions eligible?

Yes. U.S. territories or possessions are highlighted among additional eligible applicant categories.

What types of outputs is NCI aiming for at the end of an R33 project?

Based on the stated intent, NCI is aiming for technologies that are more mature and convincingly validated, with evidence supporting reliable improvements in specimen quality and reductions in pre-analytical artifacts, enabling stronger and more equitable cancer research and translational applications.

What makes a project a "strong fit" for this NOFO?

A strong fit would be a technology that better preserves or protects sample integrity (for example, stabilizing fragile analytes) and/or establishes clearer verification criteria and quality assessment/quality control methods so users can determine if a specimen is fit for its intended molecular or cellular analysis.

Does the NOFO emphasize real-world usability?

Yes. The description emphasizes performance characteristics for real-world use (reproducibility, robustness across operators/sites, sensitivity to common handling variations) and practical technologies intended to reduce pre-analytical variability.

What does the NOFO mean by "exploratory" if it is not early feasibility?

The projects are described as exploratory in the sense that they advance an emerging approach, but they should be grounded in data and focused on producing convincing validation evidence rather than speculative concepts.

What is the activity area and CFDA number listed for this opportunity?

The activity area is health and education, and the CFDA number listed is 93.394.